NCT01631331View on ClinicalTrials.gov

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 17, 2015

Study Completion Date

May 31, 2016

Conditions
Basal Cell Carcinoma of the SkinRecurrent Skin Cancer
Interventions
DRUG

vismodegib

Given PO

PROCEDURE

Mohs surgery

Undergo Mohs surgery

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University Hospitals Cleveland Medical Center

OTHER

lead

Stanford University

OTHER

NCT01631331 - Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) | Biotech Hunter | Biotech Hunter